CareDx, Inc. $CDNA Shares Bought by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. grew its position in CareDx, Inc. (NASDAQ:CDNA) by 40.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,740,064 shares of the company’s stock after acquiring an additional 504,473 shares during the period. Amova Asset Management Americas Inc. owned about 3.38% of CareDx worth $25,283,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Allworth Financial LP purchased a new position in shares of CareDx in the 2nd quarter valued at about $40,000. State of Alaska Department of Revenue purchased a new stake in shares of CareDx in the third quarter valued at approximately $43,000. Quantbot Technologies LP acquired a new position in shares of CareDx during the 3rd quarter worth approximately $89,000. Tower Research Capital LLC TRC lifted its position in shares of CareDx by 120.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after buying an additional 4,160 shares in the last quarter. Finally, RiverPark Advisors LLC purchased a new position in shares of CareDx during the 2nd quarter valued at approximately $149,000.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CDNA shares. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research report on Tuesday, January 6th. Wells Fargo & Company raised their price target on shares of CareDx from $18.00 to $21.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Weiss Ratings cut CareDx from a “hold (c-)” rating to a “sell (d)” rating in a report on Friday, February 27th. BTIG Research increased their target price on CareDx from $25.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $27.33.

Insider Transactions at CareDx

In other news, CEO John Walter Hanna, Jr. sold 19,280 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total transaction of $407,964.80. Following the completion of the transaction, the chief executive officer directly owned 597,405 shares in the company, valued at approximately $12,641,089.80. This represents a 3.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 29,636 shares of company stock worth $625,949 over the last ninety days. 4.40% of the stock is owned by company insiders.

CareDx Stock Up 1.4%

NASDAQ CDNA opened at $19.06 on Thursday. CareDx, Inc. has a 52 week low of $10.96 and a 52 week high of $21.49. The business’s fifty day simple moving average is $19.58 and its 200-day simple moving average is $16.99. The firm has a market cap of $976.25 million, a PE ratio of -47.65 and a beta of 2.52.

CareDx (NASDAQ:CDNA) last issued its earnings results on Tuesday, February 24th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.12). The firm had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $102.76 million. CareDx had a negative return on equity of 6.50% and a negative net margin of 5.65%.CareDx’s revenue for the quarter was up 25.2% on a year-over-year basis. During the same period last year, the firm earned $0.18 earnings per share. Research analysts expect that CareDx, Inc. will post -0.9 EPS for the current year.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.